{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-108898","form_type":"8-K","ticker":"PYXS","cik":"0001782223","company_name":"Pyxis Oncology, Inc.","filed_at":"2025-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.972828+00:00","generated_at":"2026-05-17T13:20:17.923777+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Pyxis Oncology Q2 2025 net loss $18.4M, cash $90.4M; MICVO data milestones ahead","bullets":["Revenue of $2.8M from milestone payment for suvemcitug approval in China, compared to $0 in Q2 2024.","Net loss $18.4M ($0.30 per share) vs $17.3M ($0.29) in prior year; adjusted loss $15.3M.","Cash, cash equivalents and short-term investments $90.4M; runway into H2 2026.","Preliminary MICVO monotherapy data in 2L/3L HNSCC expected H2 2025; combination with pembrolizumab data also H2 2025.","R&D expenses rose to $17.1M, driven by increased MICVO manufacturing and trial costs."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-108898","json":"https://secwatch.observer/filing/0000950170-25-108898.json","markdown":"https://secwatch.observer/filing/0000950170-25-108898.md","text":"https://secwatch.observer/filing/0000950170-25-108898.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1782223/000095017025108898/0000950170-25-108898-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1782223/000095017025108898/pyxs-20250814.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T13:20:17.923777+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}